KR20220143811A - 단백질 로딩된 plga 나노구체 - Google Patents

단백질 로딩된 plga 나노구체 Download PDF

Info

Publication number
KR20220143811A
KR20220143811A KR1020227022928A KR20227022928A KR20220143811A KR 20220143811 A KR20220143811 A KR 20220143811A KR 1020227022928 A KR1020227022928 A KR 1020227022928A KR 20227022928 A KR20227022928 A KR 20227022928A KR 20220143811 A KR20220143811 A KR 20220143811A
Authority
KR
South Korea
Prior art keywords
nanospheres
protein
emulsion
plga
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227022928A
Other languages
English (en)
Korean (ko)
Inventor
브록 에이 린지
저스틴 이 마르켈
라이언 에이 라신스키
자빈 누레
Original Assignee
웨스트 버지니아 유니버시티
웨스트 버지니아 유니버시티 보드 오브 거버너스 온 비해프 오브 웨스트 버지니아 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 웨스트 버지니아 유니버시티, 웨스트 버지니아 유니버시티 보드 오브 거버너스 온 비해프 오브 웨스트 버지니아 유니버시티 filed Critical 웨스트 버지니아 유니버시티
Publication of KR20220143811A publication Critical patent/KR20220143811A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020227022928A 2019-12-05 2020-12-04 단백질 로딩된 plga 나노구체 Pending KR20220143811A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944191P 2019-12-05 2019-12-05
US62/944,191 2019-12-05
PCT/US2020/063314 WO2021113638A1 (en) 2019-12-05 2020-12-04 Protein-loaded plga nanospheres

Publications (1)

Publication Number Publication Date
KR20220143811A true KR20220143811A (ko) 2022-10-25

Family

ID=76221229

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227022928A Pending KR20220143811A (ko) 2019-12-05 2020-12-04 단백질 로딩된 plga 나노구체

Country Status (11)

Country Link
US (3) US12214046B2 (https=)
EP (1) EP4072536A4 (https=)
JP (1) JP7818514B2 (https=)
KR (1) KR20220143811A (https=)
CN (1) CN115335041A (https=)
AU (1) AU2020396557A1 (https=)
BR (1) BR112022010952A2 (https=)
CA (1) CA3160922A1 (https=)
IL (1) IL293607A (https=)
MX (1) MX2022006824A (https=)
WO (1) WO2021113638A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025101020A1 (ko) * 2023-11-10 2025-05-15 아주대학교산학협력단 패티게이션 기술을 적용한 쿠에티아핀-지방산 접합체 나노입자 및 이의 장기 지속형 주사제 용도

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021113638A1 (en) 2019-12-05 2021-06-10 West Virginia University Protein-loaded plga nanospheres
CN116855571B (zh) * 2023-06-26 2025-03-21 中国农业大学 Plga纳米球病毒示踪剂及其制备方法与应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
FR2793684B1 (fr) 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US20040003402A1 (en) 2002-06-27 2004-01-01 Digeo, Inc. Method and apparatus for automatic ticker generation based on implicit or explicit profiling
US6974862B2 (en) 2003-06-20 2005-12-13 Kensey Nash Corporation High density fibrous polymers suitable for implant
US20070026005A1 (en) * 2003-09-09 2007-02-01 Sung Young C Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
KR100622996B1 (ko) * 2005-03-03 2006-09-14 한국과학기술원 약물이 봉입된 비다공성 고분자 미립 담체 및 이의 제조방법
WO2007074604A1 (ja) 2005-12-26 2007-07-05 Ltt Bio-Pharma Co., Ltd. 水溶性非ペプチド性低分子薬物含有ナノ粒子
US10265407B2 (en) 2007-02-15 2019-04-23 Yale University Modular nanodevices for smart adaptable vaccines
EP2251006B1 (en) 2008-02-22 2017-07-19 Toray Industries, Inc. Microparticles and pharmaceutical compositions thereof
US9972047B1 (en) 2008-04-18 2018-05-15 Capital One Services, Llc Systems and methods for performing a purchase transaction using rewards points
US20090281888A1 (en) 2008-05-09 2009-11-12 Li-Cheng Richard Zai Method And Apparatus For Establishing Time-Based Loyalty Relationship
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
WO2011063177A1 (en) 2009-11-20 2011-05-26 Mobisave Corporation System and method of electronically verifying required proof-of-performance to secure promotional rewards
WO2011119262A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
US9782342B2 (en) * 2010-10-11 2017-10-10 Wichita State University Composite magnetic nanoparticle drug delivery system
BR112014006596A2 (pt) * 2011-09-21 2017-03-28 Yissum Res Dev Co nanopartícula que encapsula uma pluralidade de nanocarreadores, composição, uso de uma nanopartícula, kit, sistema de entrega, processo para obter uma nanopartícula, e, processo de nanoaspersão para obter as nanopartículas
US9562015B2 (en) * 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
CA2869748C (en) * 2012-04-12 2017-10-24 Yale University Vehicles for controlled delivery of different pharmaceutical agents
WO2013166487A1 (en) 2012-05-04 2013-11-07 Yale University Highly penetrative nanocarriers for treatment of cns disease
US9724304B2 (en) 2012-06-14 2017-08-08 Temple University—Of the Commonwealth System of Higher Education Nanospheres for therapeutic agent delivery
US9308172B2 (en) 2012-10-26 2016-04-12 Board Of Trustees Of Michigan State University Device and method for encapsulation of hydrophilic materials
CA2929277C (en) * 2013-11-01 2018-01-16 Yale University Delivery vehicles comprising il-2 and losartan
WO2016061201A1 (en) * 2014-10-14 2016-04-21 The Brigham And Women's Hospital, Inc. Nanoparticles and methods of use
CN104622795B (zh) * 2015-01-28 2017-12-08 杭州市萧山区中医院 一种多细胞因子序贯缓释微球‑水凝胶复合系统及其制备方法
CN108064176A (zh) 2015-04-22 2018-05-22 库瑞瓦格股份公司 用于治疗肿瘤疾病的含有rna的组合物
US20170056327A1 (en) * 2015-08-25 2017-03-02 The Methodist Hospital Micro/nano composite drug delivery formulations and uses thereof
WO2019162951A1 (en) * 2018-02-26 2019-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Drug delivery systems
EP3987054A4 (en) 2019-06-18 2023-06-14 Biomeme Incorporated SAMPLE ANALYSIS SYSTEMS
WO2021113638A1 (en) 2019-12-05 2021-06-10 West Virginia University Protein-loaded plga nanospheres

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025101020A1 (ko) * 2023-11-10 2025-05-15 아주대학교산학협력단 패티게이션 기술을 적용한 쿠에티아핀-지방산 접합체 나노입자 및 이의 장기 지속형 주사제 용도

Also Published As

Publication number Publication date
JP2023504282A (ja) 2023-02-02
US20250064949A1 (en) 2025-02-27
CN115335041A (zh) 2022-11-11
US20250073343A1 (en) 2025-03-06
EP4072536A4 (en) 2025-01-15
US20230070180A1 (en) 2023-03-09
IL293607A (en) 2022-08-01
AU2020396557A1 (en) 2022-06-23
EP4072536A1 (en) 2022-10-19
CA3160922A1 (en) 2021-06-10
WO2021113638A1 (en) 2021-06-10
BR112022010952A2 (pt) 2022-09-06
MX2022006824A (es) 2022-09-19
JP7818514B2 (ja) 2026-02-20
US12214046B2 (en) 2025-02-04

Similar Documents

Publication Publication Date Title
US20250073343A1 (en) Protein-loaded plga nanospheres
US10987314B2 (en) Antigen-specific, tolerance-inducing microparticles and uses thereof
Xu et al. Prevention of colorectal cancer liver metastasis by exploiting liver immunity via chitosan-TPP/nanoparticles formulated with IL-12
JP6887685B2 (ja) ナノ粒子の細胞表面共役
JP5579586B2 (ja) 腫瘍ワクチン
US6193970B1 (en) Controlled release of pharmaceutically active substances for immunotherapy
Jahan et al. Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine
CN111184684B (zh) 一种红细胞凝胶递释系统及其制备方法与应用
JP2019537600A (ja) ポリマーナノ粒子
WO2018047797A1 (ja) 免疫刺激剤
Lacinski et al. Synthesis, characterization, and in vivo cytokinome profile of IL‐12‐loaded PLGA nanospheres
HK40083735A (en) Protein-loaded plga nanospheres
JP4688254B2 (ja) 腫瘍ワクチン
JP3492671B2 (ja) 免疫アジュバント
Lacinski et al. Optimizing the synthesis of interleukin‐12‐loaded PLGA nanospheres (rmIL‐12ns) via ultrasonication for treatment of metastatic osteosarcoma
EP2925297B1 (en) Composition comprising cytokine macro-aggregates
CN118436806A (zh) 一种基于PLGA的OVA-aPD1纳米/微米球混合制剂及其制备方法和应用
CN119185522A (zh) 一种载细菌全抗原的plga微球疫苗及其制备方法与应用
CN121081647A (zh) Dc疫苗、载药纳米颗粒及其制备方法和应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902